1/29
Looks like no tags are added yet.
Which of the following medications is available in blister packaging? Select all that apply.
A
Tacrolimus (Envarsus XR)
B
Tacrolimus (Astagraf XL)
C
Sirolimus (Rapamune)
D
Everolimus (Zortress)
B, C, D
Answer b is correct. Extended-release tacrolimus capsules (Astagraf XL) are available as 0.5-mg, 1-mg, and 5-mg capsules that are supplied in square bottles as well as in blister cartons.
Answer a is incorrect. Extended-release tacrolimus tablets (Envarsus XR) are available as 0.75-mg, 1-mg, and 4-mg tablets that are supplied in round HDPE bottles with twist-off caps.
Answer c is correct.Sirolimus (Rapamune) tablets are available as 0.5-mg and 1-mg triangular-shaped tablets that are supplied in both a bottle and Redipak cartons (10 blister cards of 10 tablets each). It is also available as a 2-mg tablet that is only supplied in a bottle.
Answer d is correct.Everolimus (Zortress) is available as 0.25-mg, 0.5-mg, 0.75-mg, and 1-mg tablets that are packed in child-resistant blisters (6 blister strips of 10 tablets each).
DD is a liver transplant patient who presents with elevated liver function tests. She admits to not taking her immunosuppressive regimen for the past week as she was out of town and forgot her medications. The medical team wants to treat her for acute cellular rejection. Which of the following would treat acute cellular rejection most effectively?
A
Basiliximab
B
Rabbit antithymocyte globulin
C
Belatacept
D
Rituximab
B
Antithymocyte globulins deplete T cells and can be used for both induction regimens as well as treatment of acute cellular rejection.
Answer a is incorrect. While basiliximab (IL-2 receptor antagonist) can be used in induction regimens, it is not indicated for the treatment of acute cellular rejection.
Answer c is incorrect.Belatacept (costimulation blocker) can be used as part of maintenance regimen in kidney transplant patients. Belatacept is not indicated for the treatment of acute cellular rejection or for use in liver transplant patients.
Answer d is incorrect.Rituximab is a monoclonal antibody directed against CD20 on B cells. Rituximab currently has no role in the treatment of acute cellular rejection, as this type of rejection is largely mediated by T cells.
During interdisciplinary rounds the medical resident states that MJ, a 28-year-old woman who received a kidney transplantation 10 years ago, is asking about alternatives to her immunosuppression because she wants to become pregnant. Her immunosuppression regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Which of the following do you recommend?
A
Her immunosuppression regimen does not need to be altered.
B
Recommend discontinuing tacrolimus and starting sirolimus.
C
Recommend discontinuing mycophenolate mofetil and starting azathioprine.
D
Recommend discontinuing mycophenolate mofetil and starting cyclosporine.
C
.Azathioprine has a role as an alternative to the teratogenic immunosuppressant agent, mycophenolate mofetil, if transplant recipients become pregnant.
During interdisciplinary rounds, the medical resident states that TK has a low white blood cell (WBC) count. TK received a combined kidney pancreas transplant 2 months ago and presented 2 days ago with hyperglycemia and elevated amylase and lipase. Acute cellular rejection of the pancreas transplant was confirmed on a subsequent biopsy. Her rejection episode is being treated with rabbit antithymocyte globulin. Her home immunosuppressive regimen consists of tacrolimus, mycophenolate mofetil, and prednisone. She is receiving antiviral prophylaxis with valganciclovir, antibacterial prophylaxis with trimethoprim-sulfamethoxazole, and antifungal prophylaxis with nystatin. Which of the following approach is most appropriate for this patient's new onset leukopenia?
A
Suggest the physician to hold her prednisone until her WBC count normalizes.
B
Suggest the physician to hold her mycophenolate mofetil until her WBC count normalizes.
C
Suggest the physician to continue her current therapy, but to closely monitor her WBC count.
D
Suggest the physician to hold her valganciclovir until her WBC count normalizes.
C
This patient's leukopenia is likely caused by rabbit antithymocyte globulin infusion. WBC count along with the rest of hematology labs should be monitored closely. If there is a significant decrease in her WBC or platelet counts, a reduction of or withholding the dose of rabbit antithymocyte globulin may be warranted.
.Prednisone usually causes leukocytosis and not leukopenia.
Answer b is incorrect. While mycophenolate mofetil can cause leukopenia, the likely agent inducing this patient's leukopenia is rabbit antithymocyte globulin. It is important to review the patient's medication administration record in this case to see if her blood sample was drawn during the infusion of rabbit antithymocyte globulin, as this will produce a significant leukopenia. However, even if the blood draw occurred after the infusion, the leukopenia is likely due to this agent, and the antiproliferative agent need not be held. This is especially true in light of her current presentation with acute cellular rejection.
Answer d is incorrect. While valganciclovir can cause leukopenia, the likely agent inducing this patient's leukopenia is rabbit antithymocyte globulin. During an episode of rejection, patients are treated with immunosuppressive intensification, and therefore are at increased risk for reactivation of latent viral infections. Therefore, care must be taken to not inaccurately hold a patient's antiviral prophylaxis, but thoroughly investigate the cause of leukopenia and act on the most likely cause.
You are counseling HD who is being discharged today. He received a living related renal transplant 3 days ago, and his postoperative course has been uncomplicated except for mild hypertension. When reconciling his home medications, you notice that the medical team has not restarted his home diltiazem. What is the most appropriate action to control his blood pressure at this point?
A
Notify the patient's medical team and request a discharge prescription for amlodipine.
B
Notify the patient's medical team and instruct the patient to resume his home regimen of diltiazem after discharge.
C
Notify the patient's medical team and request a discharge prescription for verapamil.
D
Notify the patient's medical team and request addition of diltiazem at discharge.
A
Many patients will experience higher postoperative blood pressures following solid organ transplant due to high doses of steroids and calcineurin inhibitors. Patients with preexisting hypertension may have a more difficult time maintaining blood pressure control, while patients who receive renal transplants may experience resolution of their hypertension with resolution of their kidney disease. While the nondihydropyridine calcium channel blockers, such as diltiazem and verapamil may be appropriate choices for some patients prior to transplant, they may complicate management of calcineurin inhibitors post operatively, due to their interaction mediated via CYP 3A and P-glycoprotein. Dihydropyridine calcium channel blockers, such as nifedipine and amlodipine, have less potential for clinically significant pharmacokinetic interactions with calcineurin inhibitors.
The nondihydropyridine calcium channel blockers (diltizem and verapamil) inhibit CYP3A and P-glycoprotein, resulting in elevated concentrations and toxicity of calcineurin inhibitors. These agents can be used safely, with close monitoring of trough levels of calcineurin inhibitors, but reinitiation of these agents at discharge is not appropriate.
Which of the following agents would be most appropriate to prevent a gout flare in a transplant patient who is currently receiving tacrolimus, azathioprine, and prednisone?
A
Indomethacin
B
Allopurinol
C
Diclofenac
D
Probenecid
D
.Probenecid is indicated for the prevention of gouty attacks, and is not expected to interact with any medication in this patient's immunosuppressive regimen as it is excreted renally. However, if this patient had renal insufficiency with a CrCl < 50 ml/min, this agent should be avoided.
Answer A is incorrect. Indomethicin is a nonsteroidal anti-inflammatory drug (NSAID). NSAIDs are not recommended in combination with calcineurin inhibitors such as tacrolimus due to increased potential for nephrotoxicity via decrease in renal prostaglandin production.
Answer b is incorrect.Allopurinol inhibits xanthine oxidase and is typically the drug of choice to prevent gouty attacks. The metabolite of azathioprine (6-mercaptopurine) is inactivated via xanthine oxidase. If allopurinol is administered concomitantly with azathioprine, the other metabolic pathway that produces 6-thioguanine nucleotides can be enhanced, leading to severe pancytopenia. Allopurinol should be avoided in patients who are currently receiving azathioprine.
JP is a 35-year-old man with a past medical history significant for end-stage renal disease secondary to hypertension and is admitted for kidney transplantation. JP is now post-operative day 1 from the kidney transplant and the medical team started maintenance immunosuppression with tacrolimus immediate-release (Prograf), and mycophenolate mofetil. JP had an anaphylactic reaction to Prograf. Which of the following products should he not receive as an alternative to Prograf for maintenance immunosuppression? Select ALL that apply.
A
Basiliximab
B
Envarsus XR
C
Astagraf XL
D
Cyclosporine
A, B, C
Although basiliximab is not contraindicated in individuals with an anaphylactic reaction to tacrolimus, it is not indicated for maintenance immunosuppression but rather used as induction therapy at the time of transplantation. Envarsus XR and Astagraf XL are extended-release once-daily tacrolimus formulations. Their use is contraindicated in individuals with known hypersensitivity to tacrolimus.
.Cyclosporine is a calcineurin inhibitor used in place of tacrolimus. Although inferior to tacrolimus with respect to acute rejection rates and graft survival, it may be used in patients intolerant to tacrolimus.
LJ is a 26-year-old female patient who received kidney transplantation 3 months ago. She fills her prescription for tacrolimus, mycophenolate sodium, and prednisone at your pharmacy. Which of the following represents two adverse effects specific to corticosteroids that LJ may experience?
A
Diarrhea and leukopenia
B
Alopecia and hyperglycemia
C
Water retention and osteoporosis
D
Hirsutism and nephrotoxicity
C
Water retention and osteoporosis both are adverse effects specific to corticosteroids. Water retention leads to wait gain and hypertension. It is important to ensure adequate calcium intake and screening for bone mineral density in patients taking corticosteroids chronically.
Answer a is incorrect. Diarrhea and leukopenia are adverse effects specific to mycophenolate products. Gastrointestinal adverse effects of corticosteroids include indigestion and ulcers, but diarrhea is not particularly associated with corticosteroids. Corticosteroids cause leukocytosis.
Answer b is incorrect. Alopecia and hyperglycemia are adverse effects specific to tacrolimus. Corticosteroids can cause hirsutism. Hyperglycemia is further exacerbated by the concomitant use of corticosteroids and can lead to post-transplant diabetes mellitus.
Answer d is incorrect. Hirsutism and nephrotoxicity are adverse effects specific to cyclosporine. Corticosteroids can cause hirsutism, but nephrotoxicity is not associated with corticosteroids.
Sirolimus inhibits lymphocyte proliferation to suppress the immune systems by which of the following mechanisms of action:
A
Arresting the G2-M phase of the cell cycle
B
Suppressing synthesis of IL-2
C
Arresting the G1-S phase of the cell cycle
D
Blocking CD86-mediated co-stimulation
C
The mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, inhibit lymphocyte proliferation by arresting the G1-S phase of cell cycle. These medications can be used in place of calcineurin inhibitors or mycophenolate products.
.Azathioprine is metabolized to 6-mercaptopurine, then to the active metabolites 6-thioguanine nucleotides. 6-thioguanine nucleotides disrupt both the salvage and de novo DNA and RNA synthesis, resulting in nonspecific cell cycle arrest at the G2-M phase.
Answer b is incorrect. By inhibiting calcineurin, cyclosporine (as cyclosporine-cyclophilin complex) and tacrolimus (as tacrolimus-FKBP12 complex) suppresses synthesis of interleukin (IL)-2, the cytokine that is responsible for lymphocyte activation.
Answer d is incorrect. By blocking CD86-mediated costimulation, belatacept (Nulojix) inhibits cytokine production by T cells. Belatacept is the first FDA-approved IV maintenance immunosuppressant and offers a benefit that therapeutic drug monitoring is not required.
LJ is a 26-year-old female patient who received kidney transplantation 3 months ago. She fills her prescription for tacrolimus, mycophenolate sodium, and prednisone at your pharmacy. Which of the following represents two adverse effects specific to tacrolimus that LJ may experience?
A
Diarrhea and leukopenia
B
Alopecia and hyperglycemia
C
Hypertriglyceridemia and nephrotoxicity
D
Hirsutism and gingival hyperplasia
B (kinda disagree w/question)
Alopecia and hyperglycemia are adverse effects specific to tacrolimus. Hyperglycemia is further exacerbated by the concomitant use of corticosteroids and can lead to post-transplant diabetes mellitus.
Answer a is incorrect. Diarrhea and leukopenia are adverse effects specific to mycophenolate products. Diarrhea can be associated with tacrolimus, but leukopenia is not common with tacrolimus.
Answer c is incorrect. Both cyclosporine and tacrolimus can cause nephrotoxicity, but hypertriglyceridemia is more frequently associated with mTOR inhibitors such as sirolimus and everolimus.
Answer d is incorrect. Hirsutism and gingival hyperplasia are adverse effects specific to cyclosporine. It is important to counsel patients who are initiating cyclosporine on the importance of good oral hygiene.
PW is a transplant patient taking a stable dose of cyclosporine and rosuvastatin was recently added. Which counseling information should a pharmacist provide to PW? Select all that apply.
A
Avoid grapefruit and grapefruit juice.
B
Report unexplained muscle pain, muscle weakness or dark urine.
C
Cyclosporine dose should be decreased within days after starting rosuvastatin.
D
Inform the prescriber of rosuvastatin that PW is taking cyclosporine.
A, B, D
Grapefruit (and juice) increased both blood levels of cyclosporine and rosuvastatin and thereby their side effects. Patients taking cyclosporine or rosuvastatin should avoid grapefruit and grapefruit juice.
Answer b is correct.Cyclosporine can increase rosuvastatin exposure 7 fold, resulting in increased risk for myopathy and rhabdomyolysis. Patients taking cyclosporine and rosuvastatin together should be monitored for symptoms of statin-induced myopathy.
Answer d is correct. Due to the increased risk of myopathy, rosuvastatin dose should be limited to 5 mg PO daily when used with cyclosporine. The prescriber should be informed about PW's concomitant drug and monitor him closely for statin-induced myopathy.
Answer c is incorrect.Rosuvastatin does not inhibit CYP 3A or P-glycoprotein and thus increased cyclosporine concentrations are not expected. However, an interaction like this is expected with such agents as diltiazem, voriconazole, and clarithromycin.
MT presents to your pharmacy with a prescription for everolimus (Zortress). He says that his transplant nephrologist prescribed this new medication for him because he was having side effects related to tacrolimus. What is an important counseling point you should mention to MT?
A
Everolimus is more likely to cause nephrotoxicity than tacrolimus.
B
You no longer need to avoid grapefruit juice, as it does not interact with everolimus.
C
Everolimus comes in a child-resistant blister pack that should be protected from light.
D
Everolimus does not require therapeutic drug monitoring.
C
Everolimus (Zortress) is packaged in child-resistant blister packs and should be protected from light.
Answer a is incorrect.Everolimus is an mammalian target of rapamycin (mTOR) inhibitor and may be used in place of a calcineurin inhibitor to minimize the risk of nephrotoxicity.
Answer b is incorrect.Everolimus is a substrate for cytochrome P-450 3A and P-glycoprotein, and has similar drug interaction potential to calcineurin inhibitors, including an interaction with grapefruit juice.
Answer d is incorrect. As with calcineurin inhibitors, therapeutic drug monitoring is recommended for all patients taking everolimus.
KS received kidney transplantation from his brother today. Which "triple-drug regimen" describes the most commonly used maintenance immunosuppression?
A
Cyclosporine, prednisone, and basiliximab
B
Cyclosporine, tacrolimus, and prednisone
C
Tacrolimus, mycophenolate mofetil, and rabbit antithymocyte globulin
D
Tacrolimus, mycophenolate mofetil, and prednisone
D
This regimen contains a calcineurin inhibitor (tacrolimus), an antiproliferative agent (mycophenolate mofetil), and a corticosteroid (prednisone), with three distinct mechanisms of action.
Answer a is incorrect. This regimen contains a calcineurin inhibitor (cyclosporine), a corticosteroid (prednisone), and an IL-2 receptor antagonist (basiliximab). Basiliximab is an induction agent and does not make up the maintenance regimen. This regimen should include an antiproliferative agent such as mycophenolate or azathioprine.
Answer b is incorrect. This regimen contains two calcineurin inhibitors (cyclosporine and tacrolimus) and a corticosteroid. The "triple-drug regimen" is designed to optimize therapy, without excessive toxicity. A patient should never take two calcineurin inhibitors simultaneously, as their risk for serious side effects, such as nephrotoxicity, neurotoxicity, and electrolyte disturbances are greatly increased without much added benefit. The three drugs in the triple-drug regimen should have different mechanisms of action, thus allowing decreased doses of each and therefore decreased incidence of dose-dependent side effects.
Answer c is incorrect. This regimen contains a calcineurin inhibitor, an antiproliferative agent (mycophenolate mofetil), and an antithymocyte globulin. Although rabbit antithymocyte globulin is commonly employed in kidney transplant recipients, it is used as an induction agent or treatment for rejection.
LJ is a 26-year-old female patient who received kidney transplantation 3 months ago. She fills her prescription for tacrolimus, mycophenolate sodium, and prednisone at your pharmacy. Which of the following should be included in patient counseling about mycophenolate sodium for LJ? Select all that apply.
A
Educate LJ regarding higher risks of miscarriage and birth defects.
B
Counsel LJ regarding pregnancy planning.
C
Ensure the use of acceptable contraception during the first 6 weeks of starting mycophenolate.
D
Perform pregnancy tests only before starting mycophenolate.
A, B
Patient receiving mycophenolate should be counseled regarding pregnancy/pregnancy planning, including the risk of miscarriage and birth defects.
Answer c is incorrect. Female patients of reproductive potential must use acceptable contraception during entire treatment with mycophenolate and for 6 weeks after stopping mycophenolate.
Answer d is incorrect. Pregnancy tests should be performed immediately before initiation of mycophenolate, 8 to 10 days later, and at routine follow-up visits.
Which of the following medications has an associated Risk Evaluation and Mitigation Strategy (REMS) by FDA? Select all that apply.
A
Mycophenolate mofetil
B
Mycophenolate sodium generic products
C
Belatacept
D
Tacrolimus
A, B
There is a REMS program for all products containing mycophenolate mofetil or mycophenolate sodium including generic products given their risk for teratogenicity.
Answer c is incorrect. REMS was originally required for belatacept when the FDA-approved the drug in 2011 in order to inform health care providers of the increased risk of PTLD and progressive multifocal leukoencephalopathy (PML), and to inform the patients of the serious risks associated belatacept. However, the FDA eliminated the REMS requirement in 2017.
Answer d is incorrect. There is no REMS requirement for tacrolimus.
Tacrolimus is available in which of the following dosage form(s)? Select all that apply.
A
Immediate-release capsules
B
Injection (IV)
C
Extended-release capsules and tablets
D
Transdermal patch
A, B, C
.Tacrolimus (Prograf) is available in immediate-release capsules and come in the following strengths: 0.5 mg, 1 mg, and 5 mg.
Answer b is correct.Tacrolimus (Prograf) is available as an injection for IV use and is supplied in a 5-mg/mL vials. It is diluted and administered as a 24-hour continuous infusion.
Answer c is correct. Extended-release once-daily tacrolimus is available as Envarsus XR and Astagraf XL. Envarsus XR is available as 0.75-mg, 1-mg, and 4-mg extended-release tablets. Astagraf XL is available in 0.5-mg, 1-mg, and 5-mg capsules.
AJ is a lung transplant recipient who is found to have Aspergillus on routine bronchoscopy. AJ's transplant physician wants to begin treatment with the antifungal voriconazole. The patient is currently taking prednisone, cyclosporine, azathioprine, clotrimazole, rabeprazole, co-trimoxazole, valganciclovir, and inhaled amphotericin. Which of the following medications will interact with voriconazole?
A
Prednisone
B
Azathioprine
C
Cyclosporine
D
Valganciclovir
C
.Voriconazole is a potent inhibitor of CYP 3A and P-glycoprotein. Cyclosporine is extensively metabolized via CYP 3A and also a substrate of P-glycoprotein. Voriconazole will significantly increase cyclosporine levels, and it is recommended to decrease cyclosporine dosing empirically by more than 50% to avoid toxic cyclosporine blood concentrations.
Following oral administration, valganciclovir is hydrolyzed to ganciclovir, which is then excreted renally. Therefore, no interaction is suspected between these agents.
Which of the following statement is correct about sirolimus?
A
Sirolimus is not metabolized via cytochrome P450 enzymes, thus decreasing the propensity for drug interactions.
B
Sirolimus is less nephrotoxic than calcineurin inhibitors.
C
Sirolimus is available in many different formulations, thereby facilitating ease of dosing.
D
Sirolimus does not require therapeutic drug monitoring.
B
.Sirolimus has decreased risk for nephrotoxicity compared to calcineurin inhibitors, therefore it is commonly used in calcineurin inhibitor-sparing regimens to protect patients from calcineurin inhibitor-induced renal insufficiency.
Answer a is incorrect. CYP 3A is the major metabolic pathway for sirolimus. Like cyclosporine and tacrolimus, sirolimus is affected by inducers and inhibitors of CYP 3A.
Answer c is incorrect. Sirolimus is only available orally and there is no IV formulation. Furthermore, the tablet is triangular, disallowing splitting to create unavailable tablet strengths.
Answer d is incorrect. Therapeutic drug monitoring was deemed unnecessary during clinical trials, as sirolimus was used primarily as an adjunctive agent, in the place of an antiproliferative agent. However, the risk of drug interactions and variability in pharmacokinetics warrant monitoring of sirolimus concentrations.
Which of the following vaccines will need to be administered prior to transplant as they are generally contraindicated post-transplant? Select all that apply.
A
Pneumococcal polysaccharide
B
Varicella
C
Measles, mumps, rubella (MMR)
D
Meningococcal conjugate
B, C
Varicella must be administered prior to transplant for anyone who has never been exposed to chicken pox virus and who has not been vaccinated. Some experts recommend a minimum of 4 weeks between live vaccine administration and transplantation. Live vaccines are generally contraindicated after transplant.
Answer c is correct. Measles, mumps, rubella (MMR) must be administered prior to transplant for anyone who has never been exposed to chicken pox virus and who has not been vaccinated. Some experts recommend a minimum of 4 weeks between live vaccine administration and transplantation. Live vaccines are generally contraindicated after transplant.
Answers a and d are incorrect. Pneumococcal polysaccharide and meningococcal conjugate vaccines may be given after transplant as they inactivated vaccines. Some experts recommend to wait at least 3 months after transplant prior to administering non-live vaccines as response to vaccines is diminished early after transplant due to the potent immunosuppression given immediately after transplant.
LJ is a 26-year-old female patient who received kidney transplantation 3 months ago. She fills her prescription for tacrolimus, mycophenolate sodium, and prednisone at your pharmacy. LJ presents to the hospital with symptoms concerning for a bowel obstruction. She is receiving mycophenolate sodium 720 mg PO BID. The physician wants to convert the patient from oral mycophenolate sodium to IV due to PO intolerance resulting from her bowel obstruction. Which of the following would result in comparable plasma concentrations of mycophenolic acid?
A
Mycophenolate sodium 720 mg IV BID
B
Mycophenolate sodium 1000 mg IV BID
C
Mycophenolate mofetil 720 mg IV BID
D
Mycophenolate mofetil 1000 mg IV BID
D
CellCept, or mycophenolate mofetil, is available in an oral and intravenous formulation. When converting a patient from PO Myfortic (mycophenolate sodium) to intravenous therapy, IV mycophenolate mofetil (CellCept) can be used at a therapeutically equivalent dose. 720 mg of Myfortic is equivalent to 1000 mg of CellCept.
Myfortic, or mycophenolate sodium, is an enteric-coated delayed-release oral formulation and it is not available intravenously.
Which of the following is generally considered as a narrow therapeutic ratio drug?
A
Cyclosporine
B
Prednisone
C
Mycophenolate mofetil
D
Mycophenolate sodium
A
.Cyclosporine is generally considered to have a narrow therapeutic ratio as the blood concentration ranges to effectively prevent rejection overlap with that of nephrotoxic potential, and cyclosporine concentration monitoring is required.
The FDA does not formally designate the narrow therapeutic ratio drugs. According to 21 Code of Federal Regulations (CFR) 320.33(c), narrow therapeutic ratio is defined as follows:
There is less than a twofold difference in median lethal dose (LD50) and median effective dose (ED50) values or there is less than a twofold difference in the minimum toxic concentrations and minimum effective concentrations in the blood, and
Safe and effective use of the drug products require careful titration and patient monitoring.
Which of the following should be confirmed before administering belatacept in a kidney transplant patient? Select all that apply.
A
Positive cytomegalovirus serostatus
B
Positive Epstein-Barr virus (EBV) serostatus
C
Normal renal and liver function
D
Absence of any new or worsening neurological abnormalities
B, D
.Belatacept was associated with the increased risk of post-transplant lymphoproliferative disorder predominantly involving the central nervous system. It is contraindicated in patients who are EBV seronegative or with unknown EBV serostatus.
Answer d is correct. Before each dose of belatacept, patients should be assessed for signs and symptoms of post-transplant lymphoproliferative disorder and progressive multifocal leukoencephalopathy. If the patient reports any new or worsening problems such as a new or sudden change in thinking, memory, speech, mood, behavior, vision, balance, strength, fever, night sweats, persistent tiredness, weight loss, or swollen glands, belatacept should not be administered and the patient should be referred to appropriate medical management.
Answer a is incorrect. Although positive EBV serostatus is required to receive belatacept, cytomegalovirus status is not pertinent.
Answer c is incorrect.Belatacept dose is determined based on actual body weight and does not need to be adjusted for renal or hepatic dysfunction.
The following is KM's maintenance immunosuppression regimen: Envarsus XR 4 mg by mouth once daily, mycophenolate mofetil 250 mg by mouth twice daily, and prednisone 5 mg by mouth once daily. The nurse asks you if there are any specific administration instructions regarding his immunosuppression. How do you advise the nurse?
A
There are no special administration instructions for his immunosuppressive medications.
B
Do not divide prednisone tablets in half.
C
Do not divide Envarsus XR tablets in half.
D
Open the mycophenolate mofetil capsules and have patient swallow contents.
C
Envarsus XR is an extended-release tablet and should not be swallowed whole with liquid. The tablet should not be chewed, divided, or crushed.
.Prednisone tablets have no special handling instructions and may be divided in half. Envarsus XR® is an extended-release tablet and should not be chewed, divided, or crushed. Mycophenolate mofetil is supplied in capsules and should not be opened or crushed. The capsule should be swallowed whole.
GH presents to your pharmacy with a prescription for clarithromycin. He says that his primary care physician prescribed this medication to treat community-acquired pneumonia. You review GH's medication profile and see that he received a renal transplant 2 years ago and his immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and prednisone. Which of the following would be most appropriate as your next course of action?
A
Dispense clarithromycin and counsel on avoiding grapefruit juice.
B
Contact the prescriber about the interactions between clarithromycin and tacrolimus as clarithromycin will inhibit the metabolism of tacrolimus, resulting in supratherapeutic levels and toxicity.
C
Contact the prescriber about the interactions between clarithromycin and mycophenolate mofetil as clarithromycin will inhibit the metabolism of mycophenolate mofetil resulting in supratherapeutic levels and toxicity.
D
Recommend an alternative as clarithromycin is not an appropriate therapy for community-acquired pneumonia in an immunosuppressed host.
B
.Clarithromycin is an inhibitor of CYP 3A, and therefore will inhibit the metabolism of tacrolimus, resulting in supratherapeutic concentrations and potential toxicity.
Answer a is incorrect. Avoiding grapefruit juice is a good counseling point for a patient taking clarithromycin or tacrolimus (CYP 3A substrates). However, answer B is more critical than A to avoid tacrolimus toxicity.
Answer c is incorrect. Mycophenolate mofetil is metabolized to its active metabolite, mycophenolic acid which then undergoes enterohepatic recirculation until it is eventually cleared via hepatic glucuronidation. Clarithromycin will not significantly affect mycophenolate clearance.
Answer d is incorrect. General immunosuppressed state is not a contraindication for the use of clarithromycin, as long as the organisms isolated or suspected is susceptible to this agent.
What is the drug target for the immunosuppressive agent mycophenolic acid?
A
mammalian target of rapamycin (MPA)
B
Cyclophilin
C
FKBP-12
D
Inosine monophosphate dehydrogenase (IMPDH)
D
Inosine monophosphate dehydrogenase (IMPDH) is an enzyme required for the de novo synthesis of purines, and is inhibited by mycophenolic acid (MPA) the active metabolite of the mycophenolate derivatives. This is the mechanism that allows these agents to selectively inhibit lymphocyte proliferation, as these cells are unable to utilize salvage pathways of purine synthesis.
Answer a is incorrect.Sirolimus is a selective immunosuppressant that exerts its affect via inhibition of the mammalian target of rapamyin (mTOR). Blockade of mTOR results in inhibition of lymphocyte proliferation via cell cycle arrest in the G1 to S phase.
Answer b is incorrect. Cyclophilin is the binding target of cyclosporine that facilitates inhibition of calcineurin, a phosphatase enzyme that is responsible for the dephosphorylation of nuclear factor of activated T cells (NFAT), which is a required transcription factor in the process of cytokine production. This inhibition in turn suppresses T-cell activation, and thus cellular immune response.
Answer c is incorrect. FKBP-12 is the binding target of tacrolimus that facilitates inhibition of calcineurin which results in the same outcome as inhibition by cyclosporine, although the intercellular mediators are different.
LJ is a 26-year-old female patient who received kidney transplantation 3 months ago. She fills her prescription for tacrolimus, mycophenolate sodium, and prednisone at your pharmacy. LJ approaches the counter at your pharmacy and would like you to suggest an over-the-counter (OTC) remedy for her mild headache. What would you suggest for her headache?
A
She should proceed immediately to a local emergency room as this might be a symptom of severe tacrolimus toxicity.
B
She may take OTC acetaminophen, and alert the transplant physician if the headache does not resolve.
C
She may take OTC naproxen, and alert the transplant physician if the headache does not resolve.
D
She may take OTC ibuprofen, and alert the transplant physician if the headache dose not resolve.
B
Transplant patients that are taking calcineurin inhibitors should avoid taking nonsteroidal anti-inflammatory drugs (NSAIDs) because NSAIDs cause inhibition of renal prostaglandin production and can increase the risk for nephrotoxicity induced by calcineurin inhibitors. Therefore, acetaminophen is the preferred OTC analgesic agent.
Answer a is incorrect. While neurotoxicity such as headaches and tremors are associated with supratherapeutic calcineurin inhibitor concentrations, headache is a common side effect, especially a few hours after the dose is administered, as this is the time when drug levels in the body are highest. Because her headache is only mild, the most reasonable suggestion would be to try the OTC analgesic acetaminophen, and if the headache does not dissipate, to contact the transplant physician. If the headache were severe, immediate medical attention would be warranted.
JP is a 35-year-old man with a past medical history significant for end-stage renal disease secondary to hypertension and is admitted for kidney transplantation. The surgical team has decided to use antithymocyte globulin (ATG) as induction immunosuppression for JP and asks you to provide dosing recommendations. What do you recommend?
A
Rabbit ATG 1.5 mg/kg IV once daily × 1-3 doses
B
Rabbit ATG 1.5 mg/kg IV once daily × 4-7 doses
C
Equine ATG 1.5 mg/kg IV once daily × 1-3 doses
D
Rabbit ATG 3 mg/kg IV twice daily × 4-7 doses
B
The FDA-approved rabbit ATG dosing regimen for the prevention of acute rejection in kidney transplantation is 1.5 mg/kg × 4-7 doses.
Answer c is incorrect. Equine ATG is not FDA-approved as induction immunosuppression. Furthermore, the commonly used dose of equine ATG (10-15 mg/kg) is 10 times that of rabbit ATG.
ST is a kidney transplant patient whose biopsy showed cellular rejection. Select the statement that most accurately describes mechanism of ST's rejection.
A
An orchestrated immune response that involves alloantigen presentation via antigen presenting cells (APCs) that then leads to alloreactive T lymphocytes.
B
A cytotoxic immune response mediated via preformed antibodies against antigens present on vascular endothelium.
C
A slow process of graft fibrosis and arteriopathy, which results in graft dysfunction.
D
A process which inhibits the entire process of immune activation, including antigen presentation by APCs, the release of cytokines such as interleukin (IL)-1, IL-2, IL-6 and tumor necrosis factor (TNF) α, and subsequently lymphocyte proliferation.
A
This is a description of acute cellular rejection (ACR). ACR requires the production of alloreactive T cells via T cell binding at the T cell receptors on APCs, with subsequent cytokine release and immune activation.
Antibody-mediated rejection typically occurs hours to days after transplant if donor-specific antibodies are present at the time of transplant. This type of rejection most frequently results from mismatched blood types and positive cross-matches, and the incidence has decreased with the advent of screening.
Answer c is incorrect. This is a description of chronic rejection. The etiology of chronic rejection is not clearly known and there is no treatment for this condition. However, ACR has been shown to be a primary risk factor for the development of chronic rejection, thus prevention is a key modifier.
Answer d is incorrect. This is a description of the ubiquitous immunosuppressive action that steroids have on immune response.
KS is a 17-year-old boy who is waiting for kidney transplantation. He states that he has been doing research on the Internet and heard that acute cellular rejection (ACR) is a major complication of kidney transplantation. What can a pharmacist counsel him regarding the time frame for risk of ACR after transplant?
A
The risk is greatest during the first hours to days after transplantation.
B
The risk is greatest during the first several months after transplantation.
C
The risk increases with increased time from transplant.
D
The risk is the same regardless of time after transplant.
B
The time period of greatest risk for ACR is during the first 6 months after transplantation, with risk dropping precipitously after 1 year.
Answer a is incorrect. This time period describes the time of greatest risk for antibody-mediated rejection.
Answer c is incorrect. The further out from transplant a patient is, the less likely they are to have an episode of ACR. However, as time passes from date of transplant, a patient is at increased risk for chronic rejection, especially if they have a history of multiple episodes of ACR.
AT is a 55-year-old man who is being evaluated for transplantation. Upon reviewing his immunization record, you noticed that he has not received a shingles vaccine. What would be most appropriate for AT's vaccination?
A
Shingles vaccine is not indicated for AT because he is younger than 60 years.
B
Give a live-attenuated zoster vaccine and immediately list him for transplantation.
C
Give a recombinant subunit zoster vaccine now and wait for at least 2 weeks prior to listing him for transplantation.
D
List AT for transplantation immediately and give a live-attenuated zoster vaccine after transplantation.
C
Subunit zoster vaccine is inactive and can be used in transplant candidates and recipients. Ideally, inactivated vaccines should be given at least 2 weeks prior to transplantation for an adequate immune response.
Shingles vaccines are indicated for adults ≥50 years of age. Since AT has not received a shingles vaccine, he should be vaccinated preferably prior to transplantation.
Answer b is incorrect. Although live-attenuated vaccines can be given to transplant candidates, it is recommended to wait for at least 4 weeks to ensure that vaccine-related viral replication has resolved prior to transplantation. Subunit vaccine is preferred over live-attenuated vaccines to avoid delays in transplantation.